Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Accord Healthcare Ltd.

https://www.accord-healthcare.com/

Latest From Accord Healthcare Ltd.

Accord Adds To Crowded EU Trastuzumab Market

Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.

Biosimilars Approvals

EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab

GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.

Europe Approvals

Vertex's Triple CF Combo Gets EU Approval Nod; Rejection For Daiichi Sankyo

EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.

Drug Review Europe

Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

Biosimilars Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register